Is Novo Nordisk (NVO) One of the Best Low Volatility Stocks to Buy Under $50?
Key takeaways
- Is Novo Nordisk (NVO) One of the Best Low Volatility Stocks to Buy Under $50?
- Novo Nordisk A/S (NYSE:NVO) is a global healthcare company specializing in diabetes care.
- While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk.
Is Novo Nordisk (NVO) One of the Best Low Volatility Stocks to Buy Under $50? Noor Ul Ain Rehman Sun, June 28, 2026 at 2:09 AM GMT+7 2 min read NOVO-B.CO NVO Novo Nordisk A/S (NYSE:NVO) is one of the best low volatility stocks to buy under $50. Novo Nordisk A/S (NYSE:NVO) announced on June 11 that the Wegovy® pill has been approved in the UK as an adjunct to a reduced-calorie diet and increased physical activity, offering a first-of-its-kind alternative to injectable treatments for adults. The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) approved the Wegovy® pill. Wegovy is an oral glucagon-like peptide-1 receptor agonist licensed for weight management in adults living with obesity (initial Body Mass Index (BMI) ≥30 kg/m2), or overweight (BMI ≥27 kg/m2 to <30 kg/m2), with at least one weight-related condition.
Sebnem Avsar Tuna, general manager at Novo Nordisk UK, stated that the approval marks a significant milestone for obesity care in the UK, as people living with obesity have access to a GLP-1 treatment in a daily pill for the first time, which allows them "the choice and flexibility of oral treatment to support their long-term weight management".
Novo Nordisk A/S (NYSE:NVO) is a global healthcare company specializing in diabetes care. It develops, discovers, manufactures, and markets pharmaceutical products. Its operations are divided into two business segments: biopharmaceuticals and diabetes and obesity care. The latter segment covers GLP-1, insulin, and other protein-related products.